Unaudited financial results for the quarter and nine months ended December 31, 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Pharmaids Pharmaceuticals reported weak standalone Q3 FY26 results with revenue from operations of just Rs. 83.28 lakhs, sharply down from Rs. 596.55 lakhs in the previous quarter, though on a year-on-year basis the 9-month standalone revenue jumped to Rs. 791.36 lakhs from Rs. 220.84 lakhs. On a consolidated basis, 9-month revenue grew 41% YoY to Rs. 2,069.85 lakhs (from Rs. 1,467.93 lakhs). Losses, however, continued to widen: standalone loss for 9M FY26 stood at Rs. (912.51) lakhs versus Rs. (422.28) lakhs a year ago, while consolidated loss rose to Rs. (1,048.70) lakhs from Rs. (870.21) lakhs. Exceptional items of Rs. 313.08 lakhs (standalone) and Rs. 255.40 lakhs (consolidated) were recorded. The company also disclosed discontinuation of its lease with Koye Lifesciences Private Limited effective December 1, 2025. The auditor (PPKG & Co) issued an unqualified limited review report. Other equity at Rs. 2,852.10 lakhs (standalone) is now well below the Rs. 3,526.78 lakhs paid-up capital, indicating heavily eroded net worth.
The deepening losses and eroded equity base are serious red flags for shareholders despite revenue growth on a consolidated basis. The stock is likely to remain under pressure until the company demonstrates a credible path to profitability.